How can OpenBiome can better support rigorous trials in pursuit of an FDA-approved microbiome-based product for C. difficile, while maintaining critical access to FMT for patients when existing treatments have failed?

I welcome your thoughts on this question. You may reach me directly at carolyn@openbiome.org or by submitting comments through this form.

 
Name
Name